CardioHeartConnect: Home Peloton cardiac rehab after TAVR
Official title: CardioHeartConnect: Commercially Available Fitness mHealth for Cardiac Rehabilitation Among Individuals Recovering From Transcatheter Aortic Valve Replacement
Run by University of Colorado, Denver · NCT07008911 · Data updated 2026-11-12
This trial tests whether an eight-week home-based Peloton program paired with a smartwatch helps people recovering from TAVR become more active and improve heart-related health compared with educational materials.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Status | Recruiting |
| Started | August 29, 2025 |
| Main results expected | August 1, 2029 |
| Study ends | August 1, 2029 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT07008911 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults in the United States who are community-dwelling, recovering from TAVR, considered appropriate for cardiac rehabilitation referral, able to stand, able to use a phone/tablet/computer to view Peloton content, and able to speak and understand English.
✕Probably not a fit
Patients who cannot use the Peloton app or a smartwatch, non-English speakers, those judged inappropriate for cardiac rehabilitation referral, or those who require supervised in-person rehabilitation are unlikely to benefit from this home-based program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
CardioHeartConnect randomizes 200 patients recovering from transcatheter aortic valve replacement to an eight-week home-based cardiac rehabilitation program delivered through Peloton modules and supported by the Ortus-iHealth platform, or to an attention control receiving American College of Cardiology educational materials. All participants receive a smartwatch and remote data capture from wearables, surveys, and electronic health records with assessments at baseline, 8 weeks, and 12 months. The primary outcome is change in average daily steps at 8 weeks, and secondary outcomes include functional capacity, cardiovascular health metrics, quality of life, self-efficacy, safety events, and participation in traditional cardiac rehab. The trial emphasizes remote delivery to improve access for patients with comorbidities or those in rural and underserved areas.
Why it matters
Potential benefit: If successful, it could broaden access to effective cardiac rehabilitation after TAVR and increase physical activity, functional capacity, and quality of life without requiring in-person attendance.
How similar studies have gone: Home-based and digital cardiac rehabilitation programs have improved uptake and activity in other cardiac populations, but use of commercial platforms like Peloton specifically after TAVR is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Appropriate for cardiac rehabilitation (CR) referral, as determined by the UCHealth Structural Heart \& Valve Clinic team * Community-dwelling * Reside in the United States * Able to speak and understand English * Able to provide informed consent * Able to stand with or without an assistive device * Able to see and hear content on the Peloton App via phone, tablet, or computer Exclusion Criteria: \- Determined to be inappropriate for cardiac rehabilitation referral by the UCHealth Structural Heart and Valve Clinic team
Where it's running
-
UCHealth Structural Heart and Valve Clinic
Aurora, Colorado, United States Recruiting
Study contacts
- Principal investigator: Jennifer Portz, PhD, MSW — University of Colorado, Denver
- Study coordinator: Joshua Rosen
- Email: joshua.rosen@cuanschutz.edu
- Phone: 303-724-1889
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EmStop Embolic Protection System for TAVR in Aortic Valve Stenosis
This study tests whether the EmStop protective device can safely capture and remove debris during transcatheter aortic valve replacement in adults with severe aortic valve stenosis.
-
Tracking progression and consequences of heart valve disease
This project will follow adults with moderate or worse valve disease to see if clinical tests and imaging can predict when their condition will get worse.
-
Investigating multiple and mixed heart valve diseases
This study looks at how common different types of heart valve diseases are and their features by gathering information from patients around the world who have been diagnosed with these conditions.
-
Transcatheter Aortic Valve Replacement Registry for Outcomes and Quality Monitoring
This registry collects information from hospitals about patients undergoing TAVR to see how care and outcomes compare to guidelines and nationwide data.
-
Vericiguat to slow calcific aortic valve narrowing
This trial tests whether vericiguat can slow the progression of mild-to-moderate calcific aortic valve stenosis compared with placebo.
-
CHATEAU Registry: Real-world outcomes after TAVR
This registry collects real-world data from adults who had TAVR between 2021 and 2025 to see how they do over time and how valve performance holds up.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.